^
    Back
    Association details:
    Biomarker:miR-200-a expression
    Cancer:Non Small Cell Lung Cancer
    Drug:gefitinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    S. Karger AG
    Title:

    MicroRNA-200a Targets EGFR and c-Met to Inhibit Migration, Invasion, and Gefitinib Resistance in Non-Small Cell Lung Cancer

    Excerpt:
    ...in NSCLC cell lines that are resistant to gefitinib, a drug often used in TKI therapies to treat NSCLC, miR-200a expression is able to render the cells much more sensitive to the drug treatment.
    DOI:
    https://doi.org/10.1159/000434741